Source-grounded facts extracted from Neuronetics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Neuronetics, Inc. shareholders approved Approval of Neuronetics, Inc. 2026 Equity Incentive Plan at the 2026-05-28 meeting.
“Proposal 4: The approval of the Neuronetics, Inc. 2026 Equity Incentive Plan was approved by the Company’s stockholders by the votes set forth in the table below: 23,802,955 votes FOR the proposal 16,651,661 votes AGAINST the proposal 833,908 votes ABSTAIN 14,661,594 votes Broker Non-Votes”
Neuronetics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-28 meeting.
“Proposal 3: The approval, on a non-binding, advisory basis, of the compensation of the individual who served as our principal executive officer during 2025 and our two other most highly compensated executive officers who were serving as executive officers as of December 31, 2025 was ratified by the Company’s stockholders by the votes set forth in the table below: 29,133,360 votes FOR the proposal 11,503,294 votes AGAINST the proposal 651,870 votes ABSTAIN 14,661,594 votes Broker Non-Votes”
Neuronetics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.
“Proposal 2: The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders by the votes set forth in the table below: 47,194,967 votes FOR the proposal 6,924,816 votes AGAINST the proposal 1,830,335 votes ABSTAIN”
Neuronetics, Inc. shareholders approved Election of directors at the 2026-05-28 meeting.
“Proposal 1: All of the nominees for director were elected to serve a one-year term until the 2027 Annual Meeting, or until their respective successors are elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Avinash N. Amin, M.D. 33,982,534 7,305,990 14,661,594 Robert A. Cascella 29,304,597 11,983,927 14,661,594 Sheryl L. Conley 29,304,311 11,984,213 14,661,594 Sasha S. Cucuz 28,512,554 12,775,970 14,661,594 Glenn P. Muir 29,281,048 12,007,476 14,661,594 Daniel L. Reuvers 34,472,656 6,815,868 14,661,594 Megan R. Rosengarten 28,794,454 12,494,070 14,661,594”
Neuronetics, Inc. reported three months ended March 31, 2026 results: revenue $34.5 million, net income $(10.8) million, EPS $(0.16) per share. Guidance reaffirmed.
“Total revenue for the three months ended March 31, 2026 was $34.5 million, an increase of $2.5 million, or 8%, compared to the three months ended March 31, 2025 revenue of $32.0 million.”
Neuronetics, Inc. announced a restructuring with charges of approximately $0.2 million (up to 5% of its employees).
“On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort to optimize the Company’s cost structure. The Company expects to incur restructuring charges of approximately $0.2 million, primarily for severance and related costs, in the second quarter of 2026.”
Neuronetics, Inc. amended Amendment No. 4 to Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP (effective 2026-01-15).
“(the “Company”) entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP, (“Perceptive”) as collateral agent and other lenders defined in the agreement (the “Perceptive Facility”).”
Stephen Furlong departed as Chief Financial Officer at Neuronetics, Inc..
“On May 6, 2025, the Company announced that Stephen Furlong, who has served as Chief Financial Officer since 2019, will retire on March 31, 2026.”
Neuronetics, Inc. reported first quarter of 2024; three months ended March 31, 2024 results: revenue $17.4 million, net income $(7.9) million, or $(0.27) per share, EPS $(0.27) per share.
“therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights ● First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023 ● U.S. treatment session revenue increased by 22% versus the first quarter of 2023 ● U.S. NeuroStar Advanced Therapy system”
Wilfred E. Jaeger departed as Director at Neuronetics, Inc..
“Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.”
Joseph H. Capper departed as Director at Neuronetics, Inc..
“Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.”
John K. Bakewell departed as Director at Neuronetics, Inc..
“Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.”
Neuronetics, Inc. reported three and twelve months ended December 31, 2023 results: revenue $20.3 million; $71.3 million, net income $(5.4) million; not stated for full year, EPS $(0.19) per share; not stated for full year.
“in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 Highlights ● Fourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022 ● U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systems ● Achieved”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.